Mediterranean Diet: Heart Benefits Before and After CVD

A Mediterranean-style diet appears to matter before cardiovascular disease develops and after a diagnosis changes the stakes. The evidence is not symmetrical, and it does not prove that food can replace medication. Still, two large meta-analyses point in the same direction: higher adherence was associated with 12% lower stroke incidence in generally healthy adults and 15% lower all-cause mortality among people already living with cardiovascular disease.

That makes the diet a reasonable part of cardiovascular care across the disease timeline. It does not make olive oil a statin in a dark green bottle.

Before diagnosis: lower stroke incidence in cohort studies

The strongest recent evidence for primary prevention comes from Ungvari et al.'s 2025 meta-analysis. It pooled 21 prospective cohort studies in general or healthy adult populations without established cardiovascular disease. Participants with high Mediterranean diet adherence had a hazard ratio of 0.88 for stroke incidence compared with those with low adherence (95% confidence interval, 0.84 to 0.91; p<0.05). That is a 12% relative reduction in stroke risk.

The estimate is precise for an observational nutrition result, and the direction remained consistent across geographic and demographic subgroups. But a cohort study observes what people choose to eat; it does not randomly assign them to a diet. People who eat more vegetables, legumes, fish, nuts, and olive oil also tend to differ in education, income, smoking, physical activity, and health care use. Statistical adjustment helps, but it cannot erase every part of that healthy-user pattern.

The effect also looked smaller outside Mediterranean regions. Ungvari et al. reported an approximate hazard ratio of 0.95 in non-Mediterranean populations. Food culture, access, cooking habits, and the rest of the lifestyle surrounding the diet may affect whether results travel well. A menu with feta on it is not a study intervention.

After diagnosis: an all-cause survival association, with a major caveat

For secondary prevention, Tang et al.'s 2021 meta-analysis combined seven prospective cohort studies involving 37,879 people with established cardiovascular disease. Across follow-up periods of 3.8 to 10 years, every two-point increase in a Mediterranean diet score was associated with lower all-cause mortality: hazard ratio 0.85 (95% CI, 0.78 to 0.93).

That is a dose-response association, not a threshold effect. It also reflects a meaningful behavioral change. A two-point increase on a Mediterranean diet score requires sustained changes across several foods and habits; it is not a license to drizzle olive oil over an unchanged diet.

The result held up when the authors removed one study at a time, with estimates ranging from 0.83 to 0.91. Yet the pooled all-cause estimate had extreme heterogeneity: I²=88.9%, with p<0.001. In practical terms, the studies differed enough that the average may conceal large differences between populations. The association deserves attention, but its exact size should not be treated as universal.

The more important qualification concerns the endpoint. Tang et al. found no statistically significant association for cardiovascular-specific mortality: hazard ratio 0.91 (95% CI, 0.82 to 1.01; I²=71.6%). Because the confidence interval crosses 1.0, the analysis does not establish a reduction in deaths specifically caused by cardiovascular disease. The 15% figure applies to deaths from any cause. It may capture benefits related to metabolic disease, cancer, infection, or frailty as well as cardiovascular health, but the meta-analysis cannot separate those explanations.

What randomized evidence adds—and what it cannot settle

Randomized trials reduce some of the confounding built into diet cohorts. A 2024 systematic review of long-term randomized trials reported fewer cardiovascular events with Mediterranean diets in prevention settings. An updated 2023 systematic review likewise found evidence consistent with benefits in primary and secondary prevention.

Those reviews support the broad direction of the cohort literature, but randomized effects tend to be smaller than observational estimates. Long trials also face a very human problem: people do not maintain prescribed eating patterns with laboratory-grade consistency for years. Tang et al. found stronger mortality associations in studies lasting under seven years than in those lasting seven years or longer. Declining adherence could explain part of that pattern; survivor bias could explain part of it too. The evidence does not settle the cause.

The landmark PREDIMED trial remains relevant, but it needs careful handling. It was retracted and republished in 2018 after irregularities in randomization at several sites; the corrected analysis broadly agreed with the earlier findings. That history does not erase the trial, but it lowers confidence in treating any early PREDIMED estimate as final.

Two analyses using PREDIMED data help make the biology more plausible without proving a mechanism. A 2026 analysis of urinary polyphenol signatures found that an objective biomarker pattern associated with Mediterranean diet exposure was also associated with lower cardiovascular disease risk. This helps address the weaknesses of food questionnaires, but an exposure biomarker is not proof that polyphenols caused the lower risk. Separately, a 2021 randomized trial analysis found that a Mediterranean diet maintained platelet counts within a healthy range and reduced thrombocytopenia-related mortality risk. Platelet regulation offers one plausible hemostatic pathway, not a complete account of cardiovascular outcomes.

How does it compare with other dietary patterns?

Comparative evidence places the Mediterranean diet among the better-supported options, rather than alone on the podium. A 2024 network meta-analysis ranked it favorably for cardiovascular outcomes across dietary interventions. In people with established cardiovascular disease, a 2024 network meta-analysis of dietary patterns found it among effective approaches for improving cardiovascular risk factors, while also leaving uncertainty about which named diet performs best for every endpoint.

A 2026 review conducted for Italian national dietary guidelines also concluded that Mediterranean diet interventions show efficacy in patients with established cardiovascular disease, while a 2025 review of secondary-prevention randomized trials reflects the thinner, less consistent randomized evidence in that setting. The studies do not conflict as much as they answer different questions: cohorts estimate real-world associations over years, while trials test assigned diets under conditions where adherence and duration can limit the detectable effect.

What to do with this evidence

For someone with elevated cardiovascular risk or established cardiovascular disease, Mediterranean-style eating is a defensible addition to standard care: emphasize vegetables, legumes, fish, nuts, olive oil, and other polyphenol-rich plant foods. The expected benefit is modest in relative terms—roughly 10% to 15% in the central observational estimates—and the absolute benefit depends on baseline risk. A 12% relative reduction prevents far fewer events in a low-risk person than in someone with substantial stroke risk.

Keep prescribed statins, blood-pressure treatment, antiplatelet therapy, and diabetes medications in their proper place. The evidence supports a dietary complement, not a replacement. The honest conclusion is narrower and more useful than the usual Mediterranean-diet mythology: higher adherence is consistently associated with better cardiovascular outcomes before and after diagnosis, but the strongest secondary-prevention mortality result is all-cause mortality, not proven cardiovascular-specific survival.